Q-omics provides the consensus-scored RPS15AP30 profile across patient tissues and cancer cell-line models. RPS15AP30 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS15AP30 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, RPS15AP30 RNA expression shows 12,908 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where RPS15AP30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP30 survival associations across molecular data types. RPS15AP30 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP30 RNA expression–survival associations across cancer types. High RPS15AP30 expression shows unfavorable associations in KIRC, ACC, STAD and ESCA, but favorable associations in BRCA and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS15AP30 RNA expression.
This table summarizes RPS15AP30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP30 shows lower tumor expression in KICH and BRCA and higher tumor expression in UCEC, HNSC, STAD and LUSC. The KICH box plot shows higher RPS15AP30 RNA expression in normal versus tumor tissue (log2 FC = −0.603, t-test p = .005).
This table shows molecular features associated with RPS15AP30 in patient tissues and cancer cell lines. In patient samples, RPS15AP30 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
